Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29411996 | 1.00 | MAPT (0.47) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| SCHEMBL3421607 | 0.95 | ALDH1A1 (0.46) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| SCHEMBL2970718 | 0.94 | MAPT (0.45) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| SCHEMBL17191293 | 0.88 | MAPT (0.41) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| SCHEMBL8641417 | 0.87 | ALDH1A1 (0.39) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| SCHEMBL3582922 | 0.87 | HCAR3 (0.47) | MAPTALDH1A1HCAR3KDM4ELMNA | |
| SCHEMBL2970711 | 0.86 | MAPT (0.37) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| SCHEMBL8636703 | 0.86 | MAPT (0.50) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| SCHEMBL8639061 | 0.86 | MAPT (0.47) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| SCHEMBL15592235 | 0.83 | MAPT (0.38) | MAPTCYP3A4BLMPMP22ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160287675-A1 | TREATMENT FOR CANCER | THE UNIVERSITY OF NOTTINGHAM (GB) | 2016-10-06 | — | — | US | claimed |
| EP-1951213-B1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | MORVUS TECHNOLOGY LTD (GB) | 2012-11-14 | — | — | EP | claimed |
| US-5958682-A | VIRUS-DIRECTED ENZYME PRODRUG THERAPY FOR TREATING TUMOR CELLS CONSISTING OF A VIRAL VECTOR ENCODING BACTERIAL NITROREDUCTASE CAPABLE OF CONVERTING A PRODRUG INTO A CYTOTOXIC DRUG OPERABLY LINKED TO A PROMOTER; AND THE PRODRUG | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1999-09-28 | — | — | US | claimed |
| EP-0725826-A1 | IMPROVEMENTS RELATING TO CANCER THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-08-14 | — | — | EP | claimed |
| WO-1996014420-A1 | INDUCIBLE CELL ABLATION | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-05-17 | — | — | WO | claimed |
| WO-1995012678-A2 | IMPROVEMENTS RELATING TO CANCER THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1995-05-11 | — | — | WO | claimed |
| EP-2350664-B1 | TREATMENT OF CANCER USING THE HYPOXIA ACTIVATED PRODRUG TH-302 IN COMBINATION WITH DOCETAXEL OR PEMETREXED | IMMUNOGENESIS INC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-10398676-B2 | Use of alpha-hydroxy carbonyl compounds as reducing agents | MORVUS TECHNOLOGY LIMITED (GB) | 2019-09-03 | — | — | US | disclosed |
| US-10183062-B2 | Treatment for cancer | THE UNIVERSITY OF NOTTINGHAM (GB) | 2019-01-22 | — | — | US | disclosed |
| US-20180148463-A1 | Novel Prodrugs And Methods Of Use Thereof | Convert Pharmaceuticals SA (BE) | 2018-05-31 | — | — | US | disclosed |
| US-20180140575-A1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | GORDIAN PHARMA LIMITED (GB) | 2018-05-24 | — | — | US | disclosed |
| US-9907784-B2 | Use of alpha-hydroxy carbonyl compounds as reducing agents | MORVUS TECHNOLOGY LIMITED (GB) | 2018-03-06 | — | — | US | disclosed |
| US-9873710-B2 | Prodrugs and methods of use thereof | HEALTH INNOVATION VENTURES B.V. (NL) | 2018-01-23 | — | — | US | disclosed |
| EP-0616609-B1 | NITROANILINE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | CANCER RES CAMPAIGN TECH (GB) | 1997-06-18 | — | — | EP | disclosed |
| US-5571845-A | Nitroaniline derivatives and their use as anti-tumour agents | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-11-05 | — | — | US | disclosed |
| EP-0725826-A1 | IMPROVEMENTS RELATING TO CANCER THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-08-14 | — | — | EP | disclosed |
| WO-1996014420-A1 | INDUCIBLE CELL ABLATION | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-05-17 | — | — | WO | disclosed |
| WO-1995012678-A2 | IMPROVEMENTS RELATING TO CANCER THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1995-05-11 | — | — | WO | disclosed |
| EP-0616609-A1 | NITROANILINE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS. | CANCER RES CAMPAIGN TECH (GB) | 1994-09-28 | — | — | EP | disclosed |
| WO-1993011099-A1 | NITROANILINE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1993-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148463-A1 | Novel Prodrugs And Methods Of Use Thereof | AKR1C3, AKR1C2, AKR1B1 | MAPT 4319/4885CYP3A4 498/4885BLM 4015/4885 |
| US-10398676-B2 | Use of alpha-hydroxy carbonyl compounds as reducing agents | DERA, HOGA1, ALDOA | MAPT 3157/4885CYP3A4 456/4885BLM 3799/4885 |
| US-20180140575-A1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | DERA, HOGA1, ALDOA | MAPT 3157/4885CYP3A4 456/4885BLM 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.